Subjects from a weight loss trial who achieved any remission from Type 2 diabetes also achieved a 40% lower rate of cardiovascular disease (CVD) and a 33% lower… read more.
Abbott and Tandem Diabetes Care, Inc. a leading insulin delivery and diabetes technology company, announced that the t:slim X2 insulin pump with Control-IQ technology is the first automated… read more.
Dulaglutide. a Type 2 diabetes treatment, appears to significantly lower the risk of weight gain among women who have stopped smoking, researchers reported after a secondary analysis of… read more.
Science has named the development of glucagon like peptide-1 (GLP-1) agonists and this year’s discovery that these drugs can blunt obesity-associated health problems as its 2023 Breakthrough of The… read more.
Glucagon-like receptor agonists (GLP-1 RAs), a class of type 2 diabetes drug treatments, appear to also reduce the risk of colorectal cancer (CRC) researchers reported on Dec. 7,… read more.
The current class of anti-obesity drugs is proving remarkably effective at removing excess pounds. However, a phase 3 randomized clinical trial led by researchers at Weill Cornell Medicine… read more.
A collaboration between researchers from Cornell and University of Alberta, Edmonton, has created a new technique to treat Type 1 diabetes: implanting a device inside a pocket under… read more.
Overweight or obese adults lost more weight and shed pounds faster using Mounjaro than those taking Novo Nordisk’s rival weight loss drug (Wegovy/Ozempic)) according to an analysis of… read more.
Materials engineers at Stanford University have developed a novel hydrogel drug delivery system that transforms daily or weekly injections of diabetes and weight control drugs like Ozempic, Mounjaro,… read more.
People with diabetes (Diabetes Mellitus) are two-to-three times more likely to have depression than people without, according to the Centers for Disease Control. Current treatment includes therapy, medicine, or… read more.
A nationwide programme to reduce the risk of developing diabetes in the UK is proven beyond reasonable doubt to work, a new study reveals. The positive effects observed… read more.
Over the last four decades, insulin manufacturers have extended their periods of market exclusivity on brand-name insulin products by employing several strategies, including filing additional patents on their… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
